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doi:10.1Objective: The study objectives were to (1) compare survival after lung transplantation in patients requiring
pretransplant mechanical ventilation or extracorporeal membrane oxygenation with that of patients not requiring
mechanical support and (2) identify risk factors for mortality.
Methods: Data were obtained from the United Network for Organ Sharing for lung transplantation from October
1987 to January 2008. A total of 15,934 primary transplants were performed: 586 in patients on mechanical
ventilation and 51 in patients on extracorporeal membrane oxygenation. Differences between nonsupport patients
and those on mechanical ventilation or extracorporeal membrane oxygenation support were expressed as 2 pro-
pensity scores for use in comparing risk-adjusted survival.
Results: Unadjusted survival at 1, 6, 12, and 24 months was 83%, 67%, 62%, and 57% for mechanical venti-
lation, respectively; 72%, 53%, 50%, and 45% for extracorporeal membrane oxygenation, respectively; and
93%, 85%, 79%, and 70% for unsupported patients, respectively (P< .0001). Recipients on mechanical
ventilation were younger, had lower forced vital capacity, and had diagnoses other than emphysema. Recipients
on extracorporeal membrane oxygenation were also younger, had higher body mass index, and had diagnoses
other than cystic fibrosis/bronchiectasis. Once these variables, transplant year, and propensity for mechanical
support were accounted for, survival remained worse after lung transplantation for patients on mechanical
ventilation and extracorporeal membrane oxygenation.
Conclusion: Although survival after lung transplantation is markedly worse when preoperative mechanical sup-
port is necessary, it is not dismal. Thus, additional risk factors for mortality should be considered when selecting
patients for lung transplantation to maximize survival. Reduced survival for this high-risk population raises the
important issue of balancing maximal individual patient survival against benefit to the maximum number of pa-
tients. (J Thorac Cardiovasc Surg 2010;139:765-73)Supplemental material is available online.
Patients at the extreme of pulmonary failure who progress to
respiratory failure and require respiratory support with
mechanical ventilation or extracorporeal membrane oxygen-
ation (ECMO) before lung transplantation (LTx) receive the
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The Journal of Thoracic and CaHowever, they seem to be at high risk for early postoperative
mortality and organ wastage.2-4 Few publications describe
the outcomes of this debilitated group of patients, with
most focusing on those with cystic fibrosis5-11; further, no
single center has a large experience. Therefore, we queried
the United Network for Organ Sharing registry to (1) iden-
tify factors predisposing patients to ventilatory support, (2)
assess the impact of preoperative support on outcome after
LTx, and (3) isolate risk factors for mortality that might
help identify supported patients most likely to benefit from
LTx.
T
XPATIENTS AND METHODS
Patients
From October 16, 1987, to January 1, 2008, 15,934 primary lung trans-
plants were performed in the United States. Of these, 586 patients were on
mechanical ventilation and 51 patients were on ECMO at the time of trans-
plant. Age ranged from less than 1 year to 81 years, with a mean of 38  21
years for the mechanical ventilation group, 39  22 years for the ECMO
group, and 48  14 years for the unsupported group. Recipient, donor,
and follow-up data were obtained from the United Network for Organ Shar-
ing database. This registry includes compulsory data required by Organ
Procurement and Transplantation Network policy and is audited continu-
ously for accuracy.rdiovascular Surgery c Volume 139, Number 3 765
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
LAS ¼ lung allocation score
LTx ¼ lung transplantation
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XFollow-up
Median follow-up for all survivors was 2.9 years for those on mechanical
ventilation, 2.0 years for those on ECMO, and 3.0 years for unsupported
patients. Five percent of mechanically ventilated patients were followed
more than 11 years, 5% of patients on ECMO were followed for more
than 4 years, and 5% of unsupported patients were followed for more
than 11 years.
Data Analysis
Factors predisposing patients to ventilatory support.
Parsimonious models were developed to identify factors predisposing
patients to mechanical ventilatory support and ECMO using bagging for
variable selection.12 Variables considered were only recipient variables
related to demographics, diagnosis, lung function, pulmonary support,
comorbidities, and serology (Appendix I). Sporadic missing values were
replaced by 5-fold multiple imputation.13
Because the mechanical ventilation, ECMO, and unsupported groups
differed in a number of characteristics (Tables 1 and 2), 2 propensity scores
were developed by amplifying these parsimonious models into propensity
models for risk-adjusted outcome comparison of mechanically ventilated
versus unsupported patients and ECMO versus unsupported patients using
polytomous logistic regression analysis.14 New variables added to the
model are listed in Appendix 1. Propensity scores were then computed
for each patient for use in matching and multivariable covariate adjustment
of outcomes. A greedy matching algorithm15 was used to identify 566
unsupported patient matches for the 586 mechanically ventilated patients
and 49 matches for the 51 patients on ECMO. The 22 unmatched supported
patients were, in general, pediatric recipients (Table E1).TABLE 1. Lung transplant recipient and donor characteristics, details of
supported and unsupported patients (categoric variables)
Mechanical v
(n ¼ 5
Variable n*
Recipient
Demographic
Female 586
Diagnosis
COPD/emphysema/alpha-1 antitrypsin deficiency 586
Idiopathic pulmonary fibrosis 586
Cystic fibrosis/bronchiectasis 586
Sarcoidosis 586
Pulmonary arterial hypertension 586
Eisenmenger syndrome 586
Other 586
Surgical
Double lung transplant 586
Donor
Female 586
Smoker:>20 pack-y 500
COPD, Chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygen
766 The Journal of Thoracic and Cardiovascular SurgOutcome comparison. The 2 end points were retransplantation and
death. Nonparametric estimates of freedom from retransplantation and sur-
vival were obtained by the Kaplan–Meier method, and parametric estimates
were obtained by multiphase hazard modeling that resolved the number of
phases of instantaneous risk of death (hazard function).16 (For additional
details, see http://www.clevelandclinic.org/heartcenter/hazard.) Because
both events were found to have an early high-risk phase and a later
lower-risk phase, both unadjusted and risk-adjusted comparisons were
made according to hazard phase.
Survival value of LTx for various combinations of risk factors for mor-
tality in conjunction with mechanical ventilation or ECMO was explored by
constructing nomograms from the multivariable risk factor analyses. The
focus was on predicted 5-year survival according to certain risk factors,
with others held constant.Data Presentation
Continuous variables are summarized by mean  standard deviation
except for skewed variables, which are summarized by equivalent 15th,
50th (median), and 85th percentiles. Categoric data are summarized by fre-
quency and percentage. All analyses were performed using SAS statistical
software (SAS v9.1; SAS, Inc, Cary, NC). Survival estimates and hazard ra-
tios are accompanied by 68% confidence limits equivalent to 1 standard
error.RESULTS
Factors Predisposing Patients to Ventilatory Support
Younger patients who had poor pulmonary function, high
oxygen requirement, and poor renal function, and who were
considered more recently for LTx, were the most likely to
receive ventilatory support, either by mechanical ventilation
(Table 3) or ECMO (Table 4). These were moderately strong
predictors, with C-statistics of .75 and .79, respectively. Fig-
ure 1 portrays some of these univariably.transplantation, and in-hospital posttransplant events in ventilatory-
entilation
86)
ECMO
(n ¼ 51)
Unsupported
(n ¼ 15,297)
No. (%) n* No. (%) n* No. (%)
284 (48) 51 26 (51) 15,297 7483 (49)
114 (19) 51 15 (19) 15,297 6960 (45)
150 (26) 51 14 (27) 15,297 3369 (22)
166 (28) 51 6 (12) 15,297 2752 (18)
25 (4.3) 51 1 (2) 15,297 417 (2.7)
28 (4.8) 51 5 (9.8) 15,297 731 (4.8)
7 (1.2) 51 0 (0) 15, 297 176 (1.2)
96 (16) 51 10 (20) 15, 297 892 (5.8)
442 (76) 51 29 (57) 15,297 7481 (49)
267 (46) 51 21 (41) 15,297 5743 (38)
104 (21) 42 7 (17) 13,057 3200 (25)
ation. *Patients with data available.
ery c March 2010
TABLE 2. Lung transplant recipient and donor characteristics, details of transplantation, and in-hospital posttransplant events in ventilatory-
supported and unsupported patients (continuous variables)
Mechanical ventilation
(n ¼ 586)
ECMO
(n ¼ 51)
Unsupported
(n ¼ 15,297)
Variable n*
Mean ± SD or 15th/50th/
85th percentiles n*
Mean ± SD or 15th/50th/
85th percentiles n*
Mean ± SD or 15th/50th/
85th percentiles P
Recipient
Demographic
Age (y) 586 38  21 51 39  22 15,297 48  14 <.0001
BMI (kg/m2) 529 23  5.3 42 25  4.9 14,839 24  4.8 <.0001
Pulmonary function
O2 requirement at rest
(L/min)
433 1/3/10 43 0/2.5/10 11,843 0/2/4 <.0001
FEV1 (% of predicted) 453 34  20 38 35  21 13,975 34  21 .3
FVC (% of predicted) 450 45  17 39 52  23 13,927 50  18 <.0001
Hemodynamics
Cardiac output (L/min) 266 5.4  1.6 22 5.5  1.3 8692 5.3  1.5 .2
Mean PPA (mm Hg) 294 30  13 23 32  12 9234 28  13 <.0001
Creatinine (mg/dL) 521 0.8  0.6 44 1.0  0.4 13,227 0.9  0.6 <.0001
LAS 221 54  22 16 54  21 3302 40  11 <.0001
Surgical
Maximum lung ischemic
time (min)
491 285  120 47 294  110 13,559 277  100 .05
Hospital stay (d) 404 11/26/66 38 9/24/55 9568 9/15/34 <.0001
Donor
Age (y) 585 30  18 51 26  16 15,289 31  14 .05
BMI (kg/m2) 488 24  5.4 42 25  5.1 13,582 24  4.5 .03
BMI, Body mass index; ECMO, extracorporeal membrane oxygenation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LAS, lung allocation score; PPA,
pulmonary artery pressure; SD, standard deviation. *Patients with data available.
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In addition to longer length of stay (Table 2), mechanical
ventilation and ECMO were associated with reduced
survival, particularly early after LTx. Unadjusted survivalTABLE 3. Factors predisposing patients to mechanical ventilation
Factor Coefficient ± SE P Reliability (%)*
Younger agey 0.47  0.12 <.0001 83
Lower weightz 0.13  0.04 .0004 80
Lower FVC (% of predicted)x 0.43  0.15 .01 60
Higher oxygen requirement at
rest (L/min)k
0.07  0.01 <.0001 100
Creatinine (mg/dL)
Higher creatinine{ 0.60  0.15 <.0001 89
Higher creatinine** 0.53  0.20 .008 89
Date of transplant (y)
Later dateyy 1.52  0.46 .001 99
Earlier datezz 2.09  0.70 .003 99
COPD/emphysema/alpha-1
antitrypsin deficiency
0.66  0.12 <.0001 99
COPD, Chronic obstructive pulmonary disease; FVC, forced vital capacity; SE, stan-
dard error. C-statistic ¼ .75. *Percent of time factor appeared in 500 bootstrapped
models. yLn(age), logarithmic transformation. z(80/weight), inverse transformation.
xLn(FVC), logarithmic transformation. k(Oxygen/2.7)2, squared transformation.
{(0.8/creatinine), inverse transformation. **Ln(creatinine), logarithmic transforma-
tion. yyExp(transplant date[years since 1/1/1987]/10), exponential transformation.
zz(Transplant date [years since 1/1/1987]/10)2, squared transformation.
The Journal of Thoracic and Caat 1, 6, 12, and 24 months was 83%, 67%, 62%, and
57% for mechanical ventilation, respectively; 72%, 53%,
50%, and 45% for ECMO, respectively; and 93%, 85%,
79%, and 70% for unsupported patients, respectivelyTABLE 4. Factors predisposing patients to extracorporeal membrane
oxygenation
Factor Coefficient ± SE P Reliability (%)*
Age
Younger age 0.13  0.03 <.0001 98
Older agey 2.42  1.14 .03 98
Higher BMIz 1.09  0.50 .03 62
Cystic fibrosis/bronchiectasis 1.30  0.51 .01 71
Lower FEV1 (% of
predicted)x
0.87  0.23 .0003 55
Higher oxygen requirementk 0.07  0.02 .0001 79
Creatinine
Lower creatinine{ 0.08  0.02 .001 84
Higher creatinine** 0.96  0.32 .003 84
More recent
date of transplantyy
0.35  0.08 <.0001 98
BMI, Body mass index; FEV1, forced expiratory volume in 1 second; SE, standard er-
ror. C-statistic ¼ .79. *Percent of time factor appeared in 500 bootstrapped models.
y(Age/50)2, squared transformation. z(40/BMI), inverse transformation. xLn(FEV1),
logarithmic transformation. k(Oxygen/2.7)2, squared transformation. {(0.8/creati-
nine)2, inverse squared transformation. **Ln(creatinine), logarithmic transformation.
yyExp(transplant date [years since 1/1/1987]/10), exponential transformation.
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FIGURE 1. Relationship of lung transplant variables to the probability of requiring ventilatory support. Filled circles are averages within quintiles, and solid
lines enclosed within 68% confidence limits show the loss estimate. A, Factors predisposing patients to mechanical ventilation. B, Factors predisposing
patients to ECMO. FVC, forced vital capacity (expressed as percent of predicted); FEV1, forced expiratory volume in 1 second (expressed as percent of
predicted).
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X(Figure 2). These effects of mechanical ventilation and
ECMO on survival persisted among propensity-matched
patients (Figure 3). After adjustment for propensity score,
the hazard ratio was 1.49 (68% confidence limits,
1.39–1.58; P< .0001) for mechanically ventilated patients
compared with unsupported patients in the early hazard
phase and 2.55 (68% confidence limits, 2.09–3.12; P<
.0001) for patients on ECMO compared with unsupported768 The Journal of Thoracic and Cardiovascular Surgpatients. After the high-risk early phase, survival of patients
on ECMO was similar to that of unsupported patients, with
hazards converging at approximately 9 months (Figure 2, B).
Risk Factors for Death
Preoperative mechanical ventilation and ECMO were
strong risk factors for mortality after LTx in the multivari-
able analysis (Table 5). These were additive to other riskery c March 2010
FIGURE 2. Unadjusted mortality after LTx stratified by pretransplant
requirement for ventilatory support. A, Survival. Each symbol represents
a death; vertical bars are 68% confidence limits representing 1 standard
error, and numbers in parentheses are patients remaining at risk. Solid lines
are parametric estimates enclosed within dashed confidence limits. B, Haz-
ard function (instantaneous risk) for death. Point estimates for each group
are enclosed within 68% confidence limits. ECMO, Extracorporeal
membrane oxygenation.
FIGURE 3. Survival for propensity-matched patients. A, Preoperative me-
chanical ventilation versus unsupported groups. B, ECMO versus unsup-
ported groups. Format is as in Figure 2. ECMO, Extracorporeal
membrane oxygenation.
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Xfactors, including older recipient age (Figure 4), pulmonary
arterial hypertension, lower pretransplant forced expiratory
volume in 1 second, and longer ischemic time. There was
no interaction identified between these other risk factors
and mechanical ventilation or ECMO.
Retransplantation Comparison
Of 15,934 transplant recipients, 512 underwent retrans-
plantation. There were 21, 4, and 487 retransplants in the
mechanical ventilation, ECMO, and unsupported groups,
respectively. In the mechanical ventilation group, the first
retransplant occurred 3 days posttransplant. The first
retransplant in the ECMO group was 9 days after primary
transplant, and in the unsupported group, 4 patients under-
went retransplantation within 1 day. Freedom from retrans-
plant at 1 year was 97%, 91%, and 99% for the
mechanical ventilation, ECMO, and unsupported groups,
respectively (ECMO, P ¼ .06; mechanical ventilation,
P ¼ .9) (Figure 5).The Journal of Thoracic and CaDISCUSSION
Historically, transplant surgeons and pulmonologists
have been reluctant to recommend LTx for patients on
mechanical respiratory support.17-19 The prevailing senti-
ment was that these patients had become too sick and were
no longer in the ‘‘transplant window’’20 because survival
after LTx was unlikely.18,21 However, LTx has been
performed selectively on supported patients and reported
in a few small case series.11,22 The newly adopted LAS
places a particular focus on these patients. Need for contin-
uous mechanical ventilation is a heavily weighted factor
in the LAS model (see http://www.unos.org/resources/
frm_LAS_Calculator.asp?index¼98). Patients requiring
mechanical support in the United States now receive the
highest LAS scores and have the greatest likelihood of
undergoing transplantation, in part because of this
weighting.3 To better understand the outcomes of these
patients, this study evaluated all patients requiring
mechanical support before LTx in the United States from
1987 to 2007. LTx was uncommon for patients on
mechanical ventilation and extremely rare for those on
ECMO. Most patients undergoing transplantation from
mechanical ventilation or ECMO underwent operation inrdiovascular Surgery c Volume 139, Number 3 769
TABLE 5. Incremental risk factors for death
Factor
Coefficient
± SE P Reliability (%)*
Early hazard phase
Recipient
ECMO at transplant 1.87  0.24 <.0001 78
ECMO propensity scorey 0.12  0.05 .02
Mechanical ventilation
at transplant
1.10  0.11 <.0001 100
Mechanical ventilation
propensity scorey
0.39  0.06 <.0001
Older age 0.015  0.003<.0001 96
High weight/height ratio 2.11  0.39 <.0001 98
COPD/emphysema/
alpha-1 antitrypsin
deficiency
0.37  0.1 .0002 100
Pulmonary arterial
hypertension
0.97  0.12 <.0001 100
Cystic fibrosis/
bronchiectasis
0.28  0.12 .02 100
Eisenmenger syndrome 0.99  0.17 <.0001 100
Higher serum creatinine 0.70  0.12 <.0001 100
Lower serum
creatininez
0.033  0.01 .0007 100
Lower FEV1 (% of
predicted)
0.005  0.002 .008 82
Longer ischemic timex 0.076  0.02 <.0001 97
Year of transplantk 0.38  0.04 <.0001 100
Year of transplant{ 0.18  0.03 <.0001 100
Donor
Older age** 0.095  0.02 <.0001 76
Higher weight 0.009  0.002<.0001 92
Non-Caucasian 0.32  0.08 .01 99
Living vs cadaveric 0.91  0.19 <.0001 97
Head trauma as cause
of death
0.23  0.07 .001 78
Constant hazard phase
Recipient
ECMO at transplant 0.39  0.60 .7 20
ECMO propensity scorey 0.042  0.01 .03
Mechanical ventilation
at transplant
0.11  0.12 .4 18
Mechanical ventilation
propensity scorey
0.006  0.04 .9
Younger age 0.059  0.01 <.0001 100
Older ageyy 1.87  0.18 <.0001 100
Greater body
surface areazz
0.52  0.10 <.0001 86
Pulmonary arterial
hypertension
0.21  0.07 .003 97
Diabetes 0.20  0.05 <.0001 94
Oxygen requirementxx 0.018  0.006 .001 98
Shorter ischemic timex 0.039  0.01 .005 94
Longer ischemic timekk 0.010  0.004 .02 94
Single lung transplant 0.21  0.03 <.0001 100
Donor
Non-Caucasian 0.11  0.03 .0002 90
TABLE 5. Continued
Factor
Coefficient
± SE P Reliability (%)*
Smoker:>20 pack-y 0.10  0.03 .002 63
Diabetic 0.29  0.08 .0001 88
Anti-cytomegalovirus 0.14  0.03 <.0001 100
Head trauma as cause
of death
0.081  0.03 .003 65
COPD, Chronic obstructive pulmonary disease; ECMO, extracorporeal membrane ox-
ygenation; FEV1, forced expiratory volume in 1 second; SE, standard error. *Percent of
time factor appeared in 500 bootstrapped models. yExpressed as logit. z(Creatinine/
0.8)2, squared transformation. xExp(ischemic time/275), exponential transformation.
k(Transplant date [years since 1/1/1987]/10)2, squared transformation. {(10/transplant
date [years since 1/1/1987]), inverse transformation. **Exp(donor age/30), exponen-
tial transformation. yy(Age/50)2, squared transformation. zz(Body surface area), in-
verse transformation. xx(Oxygen/2.7)2, squared transformation. kk(275/ischemic
time)2, inverse squared transformation.
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Xrecent years; their survival was considerably worse than that
of patients not requiring mechanical support.
There were notable differences in recipient and transplant
characteristics between the 2 groups. The most striking was
that patients undergoing LTx while on mechanical support
were considerably younger, more than a decade on average.
This likely reflects the bias of treating physicians for accept-
ing higher risk and attempting more extreme therapies in
younger patients.23 In addition, it might also reflect a belief
that younger patients have greater functional reserve for with-
standing a prolonged recovery. There were also differences in
indications for LTx. Patients with emphysema were less
likely and patients with cystic fibrosis were more likely to un-
dergo transplantation from mechanical ventilation. The op-
posite finding held true for those on ECMO: Patients with
cystic fibrosis were less likely to undergo transplantation,
perhaps because of concerns over infectious complications.
Patients undergoing LTx from mechanical support were
more likely to undergo double LTx, although the reasons
for this bias and the impact on posttransplant survival are
unclear. Not surprisingly, postoperative length of stay was
markedly longer for patients undergoing LTx on mechanical
ventilation or ECMO than for unsupported patients.Principal Findings
Survival. Patients supported preoperatively by mechanical
ventilation or ECMO had markedly worse survival after LTx
than those who did not require such support. This worse
survival is not surprising. Patients requiring mechanical
support before LTx are typically deconditioned from chronic
progression to end-stage respiratory failure.24,25 Immobili-
zation combined with corticosteroids causes rapid skeletal
muscle wasting.26 Even brief periods of mechanical support
cause diaphragmatic weakness, critical to recovery after
LTx.27 Weaning from the ventilator after operation becomes
more difficult, and delayed ambulation increases susceptibil-
ity to complications such as nosocomial pneumonia and
thromboembolism.28ery c March 2010
FIGURE 5. Freedom from retransplantation. ECMO, Extracorporeal
membrane oxygenation.
FIGURE 4. Five-year survival after LTx according to recipient age. This is
a nomogram of the multivariable equation in Table 5. Except for variables
depicted, values for other risk factors were set as follows: Recipient: body
surface area ¼ 1.8 m2, weight/height ratio ¼ 0.4, pulmonary arterial hyper-
tension, FEV1¼ 35%, oxygen requirement¼ 2.7 (L/min), nondiabetic, cre-
atinine ¼ 0.89 mg/dL, transplant year ¼ 2007. Donor: age ¼ 30 years,
weight ¼ 72 kg, head trauma as cause of death, nonsmoker, nondiabetic.
ECMO, Extracorporeal membrane oxygenation.
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XThe increase in mortality was evident only in the early
phase after LTx. Patients surviving the first 6 months had
comparable long-term survival to those not requiring preop-
erative mechanical support. This period of elevated risk
likely represents prolonged recovery from surgery. There
seems to be no lasting impact on survival after this recovery
phase and no long-term injury to the graft.
For patients whose underlying pulmonary disease has
progressed to respiratory failure, LTx is most likely the
only hope for survival.29 The LAS model was designed to
balance individual waitlist urgency (likelihood of survival
within 1 year without LTx) with expected posttransplant
survival (likelihood of survival at 1 year after LTx).3 The
results of our study support the validity of the LAS.
Although survival is markedly reduced in this high-risk
population, LTx is not futile.
Our study showed that patients on ECMO before LTx
have the worst survival, even lower than that of patients
on mechanical ventilation. Until now, there have been
only a few reports on ECMO used as a ‘‘bridge to transplan-
tation,’’ and they have demonstrated mixed results.30-36
Currently, ECMO is not a scoring factor in the LAS. Future
consideration might be given to adding preoperative ECMO
support as an LAS parameter on the basis of these data.
Despite high mortality, our study shows that LTx for patients
on preoperative ECMO can have successful outcomes.
Risk factors for mortality. In multivariable analysis, me-
chanical ventilation and ECMO were strong, independent
risk factors for mortality after LTx. Others, including in-
creased recipient age, older donors, pulmonary arterial hy-
pertension, and longer ischemic time, have been well
described.2 However, there was no interaction among theseThe Journal of Thoracic and Carisk factors and mechanical ventilation or ECMO. This
points to a logical strategy for patient selection. Because me-
chanical ventilation and ECMO add important incremental
risk to LTx, optimizing survival requires minimizing other
known risk factors for mortality. Although some of these
risk factors are modifiable, such as donor age and ischemic
time, others, such as diagnosis and recipient age, are not.37
These factors must be considered before proceeding with
LTx and an objective decision made about the likelihood
of success.
Retransplantation. In addition to survival, retransplanta-
tion is an important outcome after LTx. Retransplantation
indicates severe graft failure resulting from immune and
nonimmune-mediated injury and resultant organ loss.38,39
Prevalence of retransplantation among patients requiring
preoperative mechanical ventilation or ECMO was higher
than among unsupported patients. Patients receiving
ECMO preoperatively had the highest prevalence of retrans-
plantation. Clearly, mediators that negatively affect survival
after LTx for mechanically supported patients also nega-
tively affect graft survival and increase need for retransplan-
tation.
Limitations. This study has the advantage of being able to
compare survival using large numbers of patients, including
a wide range of donor, recipient, and transplant variables. Its
limitations include lack of data collection for detailed recip-
ient factors, some of which may be important predictors of
mortality in these patients. These include signs of infection
(eg, fever or elevated white blood cell count), indicators of
nutritional status (eg, albumin and prealbumin),40,41 and
length of pre-LTx intubation time.11 In addition, it does
not consider the acute or chronic nature of respiratory
decompensation or subjective factors, such as patient moti-
vation and family support. Finally, some pretransplant
patient data gathered before the LAS are difficult to compare
with that gathered after the LAS, which requires continu-
ously updated information with changes in a patient’s clini-
cal condition.rdiovascular Surgery c Volume 139, Number 3 771
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XCONCLUSIONS
Although survival after LTx is worse when preoperative
mechanical support is necessary, it is not dismal. Those
surviving the initial period after LTx have long-term
survival comparable to those not requiring mechanical
support. Reduced survival for this high-risk population
raises an important ethical issue: balancing maximal individ-
ual patient survival against benefit to the maximum number
of patients.References
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Mason et al Cardiothoracic TransplantationAPPENDIX 1. Variables considered in analysesRecipient
Demographics:
Age (y), weight (kg), height (cm), weight/height ratio,
body surface area (m2), body mass index (kg/m2), gender,
race
Diagnosis:
Idiopathic pulmonary fibrosis, chronic obstructive pulmo-
nary disease/emphysema þ alpha-antitrypsin deficiency,
primary arterial hypertension Eisenmenger syndrome,
sarcoidosis, cystic fibrosisþbronchiectasis
Lung function:
FEV1% of predicted, FVC% of predicted
Support:
Oxygen requirement, mechanical ventilation, ECMO
Comorbidities:
Diabetes, smoking history, drug-treated hypertension,
creatinine
Serology:
ABO blood groups, panel-reactive antibodiesThe Journal of Thoracic and CaDonor
Demographics:
Age (y), body mass index (kg/m2), gender, race
Type:
Cadaveric
Comorbidities:
Smoking history, diabetes, hypertension, creatinine,
clinical infection
Cause of death:
Anoxia, head trauma, stroke
Serology:
ABO compatibility, cytomegalovirus antibodiesSurgical
Double LTx, ischemic time, year of transplantation
FEV1, Forced expiratory volume in 1 second; FVC,
forced vital capacity; ECMO, extracorporeal membrane
oxygenation; LTx, lung transplantation.rdiovascular Surgery c Volume 139, Number 3 773
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TABLE E1. Characteristics of respiratory-supported recipients who
were not propensity matched (n ¼ 22)
Characteristic n* No. (%) or Mean ± SD
Age (mo) 22 12/12/29y
Female 22 12 (55)
African-American 22 3 (14)
Height (cm) 22 69  24
Weight (kg) 22 8.3  9.1
Body surface area (m2) 22 0.40  0.25
Body mass index (kg/m2) 22 16  4.5
Diagnosis
Idiopathic pulmonary fibrosis 22 2 (9.1)
Primary arterial hypertension 22 3 (14)
Otherz 22 17 (77)
Oxygen requirement at rest (L/min1) 19 9.8  2.5
Diabetes 21 1 (4.8)
Serum creatinine (mg/dL1) 21 0.39  0.33
SD, Standard deviation. *Patients with data available. y15th, 50th, and 85th percen-
tiles. zChronic pneumonitis of infancy (1), surfactant protein B deficiency (1), other
congenital (6), non-retransplant obliterative bronchiolitis (2), pulmonary arterial dis-
ease (1), secondary pulmonary hypertension (1), nonspecified (5).
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